JP2022500047A5 - - Google Patents

Info

Publication number
JP2022500047A5
JP2022500047A5 JP2021514036A JP2021514036A JP2022500047A5 JP 2022500047 A5 JP2022500047 A5 JP 2022500047A5 JP 2021514036 A JP2021514036 A JP 2021514036A JP 2021514036 A JP2021514036 A JP 2021514036A JP 2022500047 A5 JP2022500047 A5 JP 2022500047A5
Authority
JP
Japan
Prior art keywords
approximately
genetically modified
rat
microns
compared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500047A (ja
JP7222075B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050792 external-priority patent/WO2020056122A1/en
Publication of JP2022500047A publication Critical patent/JP2022500047A/ja
Publication of JP2022500047A5 publication Critical patent/JP2022500047A5/ja
Application granted granted Critical
Publication of JP7222075B2 publication Critical patent/JP7222075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514036A 2018-09-13 2019-09-12 C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット Active JP7222075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730690P 2018-09-13 2018-09-13
US62/730,690 2018-09-13
PCT/US2019/050792 WO2020056122A1 (en) 2018-09-13 2019-09-12 Complement factor h gene knockout rat as a model of c3 glomerulopathy

Publications (3)

Publication Number Publication Date
JP2022500047A JP2022500047A (ja) 2022-01-04
JP2022500047A5 true JP2022500047A5 (https=) 2022-09-01
JP7222075B2 JP7222075B2 (ja) 2023-02-14

Family

ID=68052023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514036A Active JP7222075B2 (ja) 2018-09-13 2019-09-12 C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット

Country Status (9)

Country Link
US (1) US20220053741A1 (https=)
EP (1) EP3849304B1 (https=)
JP (1) JP7222075B2 (https=)
KR (1) KR102545031B1 (https=)
CN (1) CN112969367B (https=)
AU (1) AU2019339404B2 (https=)
CA (1) CA3112612C (https=)
ES (1) ES2974200T3 (https=)
WO (1) WO2020056122A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
CN114634932B (zh) * 2022-03-11 2023-09-05 安徽医科大学 一种新circRNA、试剂盒及用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
ES2631127T3 (es) * 2004-06-10 2017-08-28 Omeros Corporation Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
JP2011517838A (ja) 2008-04-11 2011-06-16 ユーティーシー パワー コーポレイション マニホルド・サンプを備えたバイポーラプレートおよび燃料電池
WO2010027872A1 (en) * 2008-08-27 2010-03-11 Children's Hospital & Research Center At Oakland Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis
US20120159653A1 (en) * 2008-12-04 2012-06-21 Sigma-Aldrich Co. Genomic editing of genes involved in macular degeneration
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
SG11201406547YA (en) 2012-04-25 2014-11-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
US10183988B2 (en) * 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
KR102531016B1 (ko) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
WO2017114401A1 (zh) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
CN106519030B (zh) * 2016-12-22 2020-01-07 广州泰诺迪生物科技有限公司 补体因子h抑制剂及与之相关的用途
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
SG10202111663PA (en) * 2017-02-27 2021-12-30 Regeneron Pharma Humanized model of kidney and liver disorders

Similar Documents

Publication Publication Date Title
Sequeira-Lopez et al. The microRNA-processing enzyme dicer maintains juxtaglomerular cells
US12471579B2 (en) Mouse model of DITRA disease and uses thereof
JP2021500864A5 (https=)
JP2020501582A5 (https=)
KR102602199B1 (ko) 신장 및 간 장애의 인간화 모델
Paratz et al. Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon?
JP7473548B2 (ja) Mmaの処置のための非破壊的遺伝子治療
US20180084767A1 (en) Animal models for cardiomyopathy
CN112011538A (zh) 一种Mutyh基因条件性敲除小鼠模型的构建方法
US7960606B2 (en) Mouse model of chronic heart failure and coronary atherosclerosis regression
Chey et al. CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
Hashikami et al. Establishment of X-linked Alport syndrome model mice with a Col4a5 R471X mutation
JP2022500047A5 (https=)
Aweidah et al. PRPF31-retinitis pigmentosa: Challenges and opportunities for clinical translation
WO2013188358A1 (en) Miniature swine transgenic for one or more coagulation factors
CN111485003B (zh) 一种视网膜血管疾病模型的构建方法及其应用
CN116676338A (zh) 一种遗传型转甲状腺素蛋白淀粉样变疾病模型的构建方法及应用
JP7222075B2 (ja) C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット
Ding et al. Genetic evidence that lethality in angiotensinogen-deficient mice is due to loss of systemic but not renal angiotensinogen
CN115838768A (zh) 一种基因敲除能够引起癫痫症状发生的动物模型构建的方法及应用
KR20220150295A (ko) B4galt1-매개 기능의 설치류 모델
CN114107400B (zh) 一种视网膜血管疾病模型的构建方法及其应用
CN116064526B (zh) 靶向stat3基因的向导rna、试剂盒、方法及应用
US20260123613A1 (en) Mouse model of ditra disease and uses thereof
US20200009180A1 (en) Methods of treating alzheimer's disease